Literature DB >> 26016623

Mental retardation in mucopolysaccharidoses correlates with high molecular weight urinary heparan sulphate derived glucosamine.

G V Coppa1, O Gabrielli1, L Zampini1, F Maccari2, V Mantovani2, T Galeazzi1, L Santoro1, L Padella1, R L Marchesiello1, F Galeotti2, N Volpi3.   

Abstract

Mucopolysaccharidoses (MPS) are characterized by mental retardation constantly present in the severe forms of Hurler (MPS I), Hunter (MPS II) and Sanfilippo (MPS III) diseases. On the contrary, mental retardation is absent in Morquio (MPS IV) and Maroteaux-Lamy (MPS VI) diseases and absent or only minimal in the attenuated forms of MPS I, II and III. Considering that MPS patients affected by mental disease accumulate heparan sulfate (HS) due to specific enzymatic defects, we hypothesized a possible correlation between urinary HS-derived glucosamine (GlcN) accumulated in tissues and excreted in biological fluids and mental retardation. 83 healthy subjects were found to excrete HS in the form of fragments due to the activity of catabolic enzymes that are absent or impaired in MPS patients. On the contrary, urinary HS in 44 patients was observed to be composed of high molecular weight polymer and fragments of various lengths depending on MPS types. On this basis we correlated mental retardation with GlcN belonging to high and low molecular weight HS. We demonstrate a positive relationship between the accumulation of high molecular weight HS and mental retardation in MPS severe compared to attenuated forms. This is also supported by the consideration that accumulation of other GAGs different from HS, as in MPS IV and MPS VI, and low molecular weight HS fragments do not impact on central nervous system disease.

Entities:  

Keywords:  Glucosamine; Glycosaminoglycans; Heparan sulfate; Mental retardation; Mucopolysaccharidosis

Mesh:

Substances:

Year:  2015        PMID: 26016623     DOI: 10.1007/s11011-015-9684-y

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  16 in total

1.  Agarose-gel electrophoresis for the diagnosis of mucopolysaccharidoses.

Authors:  Giovanni V Coppa; Dania Buzzega; Lucia Zampini; Francesca Maccari; Tiziana Galeazzi; Lucia Padella; Lucia Santoro; Orazio Gabrielli; Nicola Volpi
Journal:  Clin Chem Lab Med       Date:  2011-11-23       Impact factor: 3.694

2.  Urinary glycosaminoglycan (uGAG) excretion in healthy pediatric and adolescent population.

Authors:  Katarzyna Komosinska-Vassev; Dorota Blat; Paweł Olczyk; Anna Szeremeta; Agnieszka Jura-Półtorak; Katarzyna Winsz-Szczotka; Katarzyna Klimek; Krystyna Olczyk
Journal:  Clin Biochem       Date:  2014-06-20       Impact factor: 3.281

Review 3.  Urine analysis in the diagnosis of mucopolysaccharide disorders.

Authors:  J E Stone
Journal:  Ann Clin Biochem       Date:  1998-03       Impact factor: 2.057

4.  Heparan sulfate saccharides modify focal adhesions: implication in mucopolysaccharidosis neuropathophysiology.

Authors:  Julie Bruyère; Elise Roy; Jérôme Ausseil; Thomas Lemonnier; Guillaume Teyre; Delphine Bohl; Sandrine Etienne-Manneville; Hugues Lortat-Jacob; Jean Michel Heard; Sandrine Vitry
Journal:  J Mol Biol       Date:  2014-09-28       Impact factor: 5.469

5.  Mild mental retardation and low levels of urinary heparan sulfate in a patient with the attenuated phenotype of mucopolysaccharidosis type IIIA.

Authors:  Giovanni V Coppa; Fabio Galeotti; Lucia Zampini; Tiziana Galeazzi; Lucia Padella; Lucia Santoro; Francesca Maccari; Orazio Gabrielli; Nicola Volpi
Journal:  Clin Biochem       Date:  2012-12-26       Impact factor: 3.281

6.  High-throughput determination of urinary hexosamines for diagnosis of mucopolysaccharidoses by capillary electrophoresis and high-performance liquid chromatography.

Authors:  Giovanni V Coppa; Fabio Galeotti; Lucia Zampini; Francesca Maccari; Tiziana Galeazzi; Lucia Padelia; Lucia Santoro; Orazio Gabrielli; Nicola Volpi
Journal:  Anal Biochem       Date:  2010-12-13       Impact factor: 3.365

7.  Urinary uronate and sulfated glycosaminoglycan levels: markers for interstitial cystitis severity.

Authors:  Vinata B Lokeshwar; Marie G Selzer; Wolfgang H Cerwinka; Maria-Fernanda Lorenzo Gomez; Robert R Kester; Darwich E Bejany; Angelo E Gousse
Journal:  J Urol       Date:  2005-07       Impact factor: 7.450

8.  Acquired autistic behaviors in children with mucopolysaccharidosis type IIIA.

Authors:  Robin K Rumsey; Kyle Rudser; Kathleen Delaney; Michael Potegal; Chester B Whitley; Elsa Shapiro
Journal:  J Pediatr       Date:  2014-02-25       Impact factor: 4.406

9.  Urinary excretion of sulphated N-acetylhexosamines in patients with various mucopolysaccharidoses.

Authors:  J J Hopwood; H Elliott
Journal:  Biochem J       Date:  1985-08-01       Impact factor: 3.857

10.  Neuropathology in mouse models of mucopolysaccharidosis type I, IIIA and IIIB.

Authors:  Fiona L Wilkinson; Rebecca J Holley; Kia J Langford-Smith; Soumya Badrinath; Aiyin Liao; Alex Langford-Smith; Jonathan D Cooper; Simon A Jones; J Ed Wraith; Rob F Wynn; Catherine L R Merry; Brian W Bigger
Journal:  PLoS One       Date:  2012-04-27       Impact factor: 3.240

View more
  2 in total

1.  The efficacy of intracerebroventricular idursulfase-beta enzyme replacement therapy in mucopolysaccharidosis II murine model: heparan sulfate in cerebrospinal fluid as a clinical biomarker of neuropathology.

Authors:  Young Bae Sohn; Ah-Ra Ko; Mi-Ran Seong; Soyeon Lee; Mi Ra Kim; Sung Yoon Cho; Jung-Sun Kim; Makoto Sakaguchi; Takahiro Nakazawa; Motomichi Kosuga; Joo Hyun Seo; Torayuki Okuyama; Dong-Kyu Jin
Journal:  J Inherit Metab Dis       Date:  2018-07-05       Impact factor: 4.982

2.  Posterior fossa horns; a new calvarial finding of mucopolysaccharidoses with well-known cranial MRI features.

Authors:  Çağri Damar; Betül Emine Derinkuyu; Muazzez Asburçe Bike Olgaç Kiliçkaya; Mehmet Öztürk; Çiğdem Öztunali; Ayşe Gül Alimli; Öznur Leman Boyunaga; Murat Uçar; Fatih Süheyl Ezgü; Leyla Tümer; Alp Özgün Börcek; Ahmet Siğirci
Journal:  Turk J Med Sci       Date:  2020-02-03       Impact factor: 0.973

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.